Vast Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vast Therapeutics's estimated annual revenue is currently $2.4M per year.(i)
  • Vast Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Vast Therapeutics has 12 Employees.(i)
  • Vast Therapeutics grew their employee count by 0% last year.

Vast Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
VP Translational ScienceReveal Email/Phone
4
VP Product DevelopmentReveal Email/Phone
5
Medical DirectorReveal Email/Phone
6
Director AdministrationReveal Email/Phone
7
Chief Scientific OfficerReveal Email/Phone
8
Principal Scientist InhalationReveal Email/Phone
9
Executive ChairmanReveal Email/Phone
10
Principal R&D ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.8M294%N/AN/A
#2
$3.2M160%N/AN/A
#3
$83.2M4147%N/AN/A
#4
$31M15456%N/AN/A
#5
$66.6M2650%$35MN/A
#6
$10.9M546%N/AN/A
#7
$6.8M34-6%N/AN/A
#8
$165.7M21614%$250.7MN/A
#9
$26.5M132-11%$637.8KN/A
#10
$49.4M2466%N/AN/A
Add Company

What Is Vast Therapeutics?

This is the official page for Vast Therapeutics. Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breathe better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets were developed in collaboration with Dr. Mark Schoenfisch's lab at UNC Chapel Hill. Our technology gives us the unique ability to harness nitric oxide, a chemical compound that plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. By controlling its multiple mechanisms of action, we can create a platform to generate differentiated first-in-class biopolymer/macromolecules that are loaded with nitric oxide and suitable to be inhaled. Our ability to conveniently deploy nitric oxide on demand in an inhaled formulation will allow us to significantly improve patient outcomes in cystic fibrosis and other severe respiratory diseases. In vitro susceptibility testing against pathogens with our product have been completed and results indicate a broad spectrum of activity and high potency against serious bacterial pathogens. These include: Methicillin-resistant Staphylococcus aureus (MRSA) Methicillin-sensitive Staphylococcus aureus (MSSA) Pseudomonas aeruginosa Burkholderia cepacia Mycobacterium Avium-Intracellulare complex (MAC) Mycobacterium abscessus Achromobacter xylosoxidans Stenotrophomonas maltophilia Most of these pathogens present a significant threat to public health, according to the FDA. Notably, our product has shown efficacy against Mycobacterium abscessus, which is a growing pathogen among serious respiratory challenged patients.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$2.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vast Therapeutics News

2022-04-17 - Healthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report Latest Advances in New Drug Development for Women’s Health, Autism, Glaucoma, and Cancer Therapeutics

... for Women's Health, Autism, Glaucoma, and Cancer Therapeutics ... M.D.: “Nova's Psilocybin-based Therapeutics Showing Vast Promise for...

2022-04-13 - Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

... Ms. Hamill has worked across a vast array of therapeutic areas, ... of Scilex Holding and Chair and CEO of Sorrento Therapeutics, Inc.”.

2022-04-06 - BioMed Leaders: Hoth Therapeutics, Nova Mentis Life Sciences, Tonix Pharmaceuticals, and MedAvail; Visionary CEOs Report Latest Advances in Novel Therapeutics for Autism, Cancer, and Fibromyalgia, and Drug Affordability.

Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova's Psilocybin-based Therapeutics Showing Vast Potential...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M120%N/A
#2
$1M120%N/A
#3
$1.6M120%N/A
#4
$1M12N/AN/A
#5
$0.9M12-20%$7.1M